One of the most important challenges in drug development is efficient delivery of the drug molecule to the appropriate tissue to drive therapeutic benefit, while minimising side effects. For small molecule drugs, a sub-optimal ‘therapeutic index’ between the dose that delivers desired and undesired effects can limit effectiveness or even stop progression through clinical trials. For non-small molecule drugs, such as antibody-drug conjugates and oligonucleotides, the high molecular weight and other properties can limit distribution across the body and therefore prevent the drug from reaching its target and having a therapeutic effect.
Imagine an anti-cancer drug designed to kill a tumour. When given to the patient, this drug molecule needs to move through the circulatory system, navigate the extracellular environment, penetrate the tumour tissue before it gets removed and metabolised and finally enter the cell and bind to its target. All while causing minimum effect on normal cells.
Nanotechnology-based drug delivery systems hold tremendous potential to overcome these challenges. Designed to carry the drug(s) or genes specifically to the target cells or tissues, the systems release it at the desired concentrations, decreasing undesired toxicity effects. This allows for rapid evaluation of treatment efficacy in the early stages.
Over the last decade, dozens of nanomedicines have received clinical approval; with many more in pre-clinical development or in clinical trials.
For nanomedicines to be successful in the clinic, in-depth mechanistic understanding of these delivery systems is crucial. There are several critical questions that need answers:
Answering these questions will help to develop an effective drug delivery system. Once the mechanism of delivery is understood, properties of the system (size, surface charge, shape, hydrophobicity, surface chemistry) can be tailored to evade the biological barriers and achieve optimal cellular uptake in different organ systems to treat different diseases.
Cellular entry and trafficking of nanomedicines
At Medicines Discovery Catapult, we have developed a microscopy-based platform to study the cellular entry and trafficking of nanomedicines. This image-based platform provides a sensitive and robust method for evaluation of nanomedicines in cellular systems and enables to improve the drug delivery systems further.
Dr Duygu Yilmaz, PhD, is a Senior Scientist in Target Engagement & Validation at Medicines Discovery Catapult, with over 5 years’ experience in drug research and development industry.
During her PhD, Duygu worked on functionalised liposomal drug delivery systems, which would release the drug payload in a highly sensitive manner in response to stimulus in the environment. She has experience in various other drug delivery systems including polymeric nanoparticles and cell penetrating peptides. At MDC, she is developing microscopy-based methods to study intracellular entry and trafficking of nanoparticles.
By looking beyond the diffraction limit, we have established a method to quantitatively distinguish low-grade breast cancers that appear identical by traditional means. Ultimately, this nanoscale insight could expand access to novel HER2-targeted therapies by reliably identifying low expressing cohorts that would benefit from intervention.
Lipid nanoparticles (LNPs) are recognised as a leading delivery platform following clinical success in vaccine and therapeutic applications. Medicines Discovery Catapult (MDC) has built a preclinical platform to evaluate LNPs against two major challenges in the field. In this blog, Lead Scientist, Dr Phil Auckland, presents a case study of this workflow using intravenously administered LNPs encapsulating mRNA, which differentially target four major liver cell types.
Opening new avenues for RNA therapeutics through a preclinical screening and optimisation platform. In this blog, Lead Scientist Dr Phil Auckland describes how applying this platform to a library of 4,500 lipid nanoparticle (LNP) formulations enabled the identification of novel candidates with desirable mechanistic properties and in vivo functionality. Furthermore, we show that integrating multiple in vitro readouts can enhance prediction and thereby improve translation.
